📊 CTSO Key Takeaways
Investment Thesis
Cytosorbents demonstrates strong revenue growth (+14.5% YoY) and excellent gross margins (70.7%), indicating viable product-market fit. However, the company is deeply unprofitable with negative operating margins (-37.2%), burning cash operationally (-$7.6M), and faces elevated leverage (1.61x D/E) that constrains financial flexibility during a critical growth phase.
CTSO Strengths
- Revenue growth of 14.5% YoY demonstrates market demand for products
- Exceptional gross margin of 70.7% reflects pricing power and operational efficiency at production level
- Adequate near-term liquidity with current ratio of 2.11x and $7.5M cash
CTSO Risks
- Persistent operating losses (-$10.4M) and negative net income despite revenue growth signal inability to control operating expenses
- Negative operating cash flow (-$7.6M) indicates business is not self-sustaining and burning capital to fund operations
- High leverage (1.61x D/E) with $14.6M long-term debt limits financial flexibility and increases refinancing risk as cash depletes
- No insider buying activity in past 90 days suggests management lacks confidence despite operational challenges
Key Metrics to Watch
- Path to operating profitability and operating margin improvement trajectory
- Operating cash flow inflection point and cash burn rate sustainability
- Debt refinancing risks and covenant compliance given deteriorating operational metrics
CTSO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.11x current ratio provides a solid financial cushion.
CTSO Profitability Ratios
CTSO vs Healthcare Sector
How Cytosorbents Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTSO Balance Sheet & Liquidity
CTSO 5-Year Financial Trend
5-Year Trend Summary: Cytosorbents Corp's revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
CTSO Growth Metrics (YoY)
CTSO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.6M | -$2.7M | $-0.04 |
| Q2 2025 | $8.8M | $469.0K | $0.01 |
| Q1 2025 | $8.7M | -$1.5M | $-0.02 |
| Q3 2024 | $8.8M | -$2.3M | $-0.04 |
| Q2 2024 | $9.4M | -$4.1M | $-0.08 |
| Q1 2024 | $9.4M | -$6.4M | $-0.12 |
| Q3 2023 | $8.1M | -$9.2M | $-0.21 |
| Q2 2023 | $8.5M | -$6.2M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTSO Capital Allocation
CTSO SEC Filings
Access official SEC EDGAR filings for Cytosorbents Corp (CIK: 0001175151)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTSO
What is the AI rating for CTSO?
Cytosorbents Corp (CTSO) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTSO's key strengths?
Revenue growth of 14.5% YoY demonstrates market demand for products. Exceptional gross margin of 70.7% reflects pricing power and operational efficiency at production level.
What are the risks of investing in CTSO?
Persistent operating losses (-$10.4M) and negative net income despite revenue growth signal inability to control operating expenses. Negative operating cash flow (-$7.6M) indicates business is not self-sustaining and burning capital to fund operations.
What is CTSO's revenue and growth?
Cytosorbents Corp reported revenue of $27.8M.
Does CTSO pay dividends?
Cytosorbents Corp does not currently pay dividends.
Where can I find CTSO SEC filings?
Official SEC filings for Cytosorbents Corp (CIK: 0001175151) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTSO's EPS?
Cytosorbents Corp has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.